Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$3.36 -3.2%	$3.56	$2.45 ▼ $4.14	$266.64M	0.25	382,810 shs	87,070 shs
OCGN Ocugen	$1.02 -3.3%	$1.03	$0.52 ▼ $1.33	$296.69M	3.84	4.38 million shs	1.41 million shs
RNAC Cartesian Therapeutics	$10.18 -1.0%	$11.72	$8.46 ▼ $26.50	$264.29M	0.44	80,251 shs	25,703 shs
UNCY Unicycive Therapeutics	$4.13 -1.6%	$4.74	$2.83 ▼ $11.00	$73.01M	1.88	372,373 shs	341,917 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	-3.61%	-1.70%	-8.68%	+16.44%	-8.68%
OCGN Ocugen	+0.96%	+3.96%	+1.94%	+24.36%	-18.60%
RNAC Cartesian Therapeutics	-3.29%	-6.20%	-23.28%	+7.53%	-27.81%
UNCY Unicycive Therapeutics	-1.64%	-1.18%	-4.98%	-28.57%	+25.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVIR Atea Pharmaceuticals	2.4547 of 5 stars	3.3	0.0	3.3	2.5	1.3
OCGN Ocugen	1.4777 of 5 stars	3.5	2.0	2.1	0.0	0.0
RNAC Cartesian Therapeutics	2.5934 of 5 stars	3.4	2.0	2.9	3.3	0.0
UNCY Unicycive Therapeutics	2.6861 of 5 stars	3.7	2.0	2.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.50	Moderate Buy	$6.00	78.57% Upside
OCGN Ocugen	3.00	Buy	$6.00	491.13% Upside
RNAC Cartesian Therapeutics	2.80	Moderate Buy	$40.00	292.93% Upside
UNCY Unicycive Therapeutics	3.33	Buy	$60.00	1,351.38% Upside

Current Analyst Ratings Breakdown

Latest UNCY, OCGN, RNAC, and AVIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
7/9/2025	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
6/24/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/24/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$4.59 per share	N/A
OCGN Ocugen	$4.75M	62.41	N/A	N/A	$0.01 per share	101.50
RNAC Cartesian Therapeutics	$38.91M	6.80	N/A	N/A	($0.10) per share	-101.80
UNCY Unicycive Therapeutics	$680K	107.36	N/A	N/A	$0.93 per share	4.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$168.38M	-$1.61	N/A	N/A	N/A	N/A	-32.55%	-30.47%	11/6/2025 (Estimated)
OCGN Ocugen	-$54.05M	-$0.20	N/A	N/A	N/A	-1,197.71%	-255.25%	-86.79%	11/13/2025 (Estimated)
RNAC Cartesian Therapeutics	-$77.42M	-$52.83	N/A	N/A	N/A	N/A	N/A	-6.36%	11/6/2025 (Estimated)
UNCY Unicycive Therapeutics	-$36.73M	-$4.12	N/A	N/A	N/A	N/A	-243.13%	-119.46%	11/12/2025 (Estimated)

Latest UNCY, OCGN, RNAC, and AVIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	UNCY Unicycive Therapeutics	-$0.70	-$0.52	+$0.18	-$0.52	N/A	N/A
8/7/2025	Q2 2025	AVIR Atea Pharmaceuticals	-$0.46	-$0.44	+$0.02	-$0.44	N/A	N/A
8/7/2025	Q2 2025	RNAC Cartesian Therapeutics	-$0.76	$0.50	+$1.26	$0.50	$0.77 million	$0.30 million
8/1/2025	Q2 2025	OCGN Ocugen	-$0.06	-$0.05	+$0.01	-$0.05	$0.35 million	$1.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	19.17	19.17
OCGN Ocugen	9.18	1.83	1.83
RNAC Cartesian Therapeutics	N/A	13.33	13.33
UNCY Unicycive Therapeutics	N/A	2.18	2.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
OCGN Ocugen	10.27%
RNAC Cartesian Therapeutics	86.95%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	18.10%
OCGN Ocugen	4.42%
RNAC Cartesian Therapeutics	60.30%
UNCY Unicycive Therapeutics	10.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	70	79.36 million	64.99 million	Optionable
OCGN Ocugen	80	292.31 million	279.39 million	Optionable
RNAC Cartesian Therapeutics	64	26.00 million	10.32 million	Optionable
UNCY Unicycive Therapeutics	9	17.66 million	15.77 million	Not Optionable

UNCY, OCGN, RNAC, and AVIR Headlines

Recent News About These Companies

Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc.

2 hours ago | reflector.comR

Faruqi & Faruqi Reminds Unicycive Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 14, 2025 â€“ UNCY

5 hours ago | globenewswire.com

Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 14, 2025 to Discuss Your Rights – UNCY

August 28 at 4:44 PM | globenewswire.com

Investors who lost money on Unicycive Therapeutics, Inc.(UNCY) should contact The Gross Law Firm about pending Class Action - UNCY

August 28 at 8:45 AM | prnewswire.com

Shareholders of Unicycive Therapeutics, Inc. Should Contact The Gross Law Firm Before October 14, 2025 to Discuss Your Rights – UNCY

August 27 at 4:32 PM | globenewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

August 27 at 10:30 AM | prnewswire.com

Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY

August 27 at 10:00 AM | prnewswire.com

Kaplan Fox Alerts Unicycive Therapeutics, Inc. (UNCY) Investors to a Securities Class Action Lawsuit - Deadline is October 14, 2025

August 27 at 7:40 AM | theglobeandmail.com

Unicycive Therapeutics, Inc. (UNCY) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of October 14, 2025 Deadline

August 27 at 7:40 AM | theglobeandmail.com

Head to Head Contrast: Unicycive Therapeutics (NASDAQ:UNCY) vs. Protara Therapeutics (NASDAQ:TARA)

August 27 at 4:45 AM | americanbankingnews.com

Lost Money on Unicycive Therapeutics, Inc. (UNCY)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

August 27 at 2:39 AM | theglobeandmail.com

UNCY Investors with Large Losses Should Contact Robbins LLP for Information About Leading the ...

August 27 at 2:39 AM | bakersfield.comB

UNCY Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Unicycive Therapeutics, Inc. Class Action

August 26 at 7:15 PM | globenewswire.com

Shareholders that lost money on Unicycive Therapeutics, Inc.(UNCY) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

August 26 at 8:45 AM | prnewswire.com

Class Action Filed Against Unicycive Therapeutics, Inc. (UNCY) Seeking Recovery for Investors - Contact Levi & Korsinsky

August 26 at 8:45 AM | prnewswire.com

Unicycive Therapeutics to Participate in Upcoming Investor Events in September

August 26 at 7:00 AM | globenewswire.com

Shareholders of Unicycive Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 14, 2025 to Discuss Your Rights - UNCY

August 25, 2025 | theglobeandmail.com

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Unicycive Therapeutics, Inc.(UNCY) Shareholders

August 25, 2025 | globenewswire.com

Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers – UNCY

August 25, 2025 | globenewswire.com

Unicycive Therapeutics (NASDAQ:UNCY) Downgraded by Wall Street Zen to "Sell"

August 25, 2025 | marketbeat.com

UNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 24, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY, OCGN, RNAC, and AVIR Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$3.36 -0.11 (-3.03%)

As of 03:52 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Ocugen NASDAQ:OCGN

$1.01 -0.04 (-3.33%)

As of 03:51 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Cartesian Therapeutics NASDAQ:RNAC

$10.07 -0.21 (-2.04%)

As of 03:52 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Unicycive Therapeutics NASDAQ:UNCY

$4.18 -0.02 (-0.57%)

As of 03:52 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time